Olema Pharmaceuticals Inc recorded a cumulative net loss of $-205 million during 12 month ending in the second quarter 2026.
The Healthcare sector has seen employees of 284 other companies achieving higher income per employee. While Olema Pharmaceuticals Inc 's total ranking has deteriorated compared to the previous quarter from 3807 to 3828.

What is Income per Employee Ratio?

Select the Comparisons :

None ▼

Select the Ratio:

Net Income per Employee▼

None ▼

Net Income per Employee▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

OLMA Net Income per Employee	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Net Income Change	-	-	-	-	-
Net Income per Employee (TTM) $	-1,561,580	-1,413,366	-1,240,084	-1,144,710	-1,086,221
OLMA's Total Ranking	# 3828	# 3807	# 2802	# 3573	# 3143
Seq. Net Income Change	-	-	-	-	-

OLMA Company Profile >> Back to OLMA Efficiency Comparisons >> Compare OLMA Net Income per Employee to its Competitors

OLMA Net Income per Employee Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 285
Healthcare Sector	# 689
Overall Market	# 3828

Net Income per Employee Statistics
High	Average	Low
$ -117,092	$ -841,864	$ -1,413,366
(Mar 31 2021)		(Mar 31 2026)

News about Olema Pharmaceuticals Inc Income per employee

Olema Oncology Empowers Talent with Inducement Grants, Fueling Breakthroughs in Women's Cancer Treatment

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, Dec. 04, 2023 - Olema Pharmaceuticals, Inc. (Nasdaq: OLMA), a leading clinical-stage biopharmaceutical company dedicated to the development and commercialization of targeted therapies for women s cancers, announced today the issuance of stock options to three new employees. These options allow for the purchase of a total of 57,500 shares of the company s common stock, effective as of December 1, 2023.
The Compensation Committee of Olemas Board of Directors approved these inducement grants under the Company s 2022 Inducement Plan. The grants were successfully granted on December 1, 2023, and were considered an enticing offer to attract new talent to Olema, in accordance with the Nasdaq Listing Rule 5635(c)(4).
Olema Pharmaceuticals is committed to revolutionizing the treatment landscape for women s cancers, and these inducement grants exemplify the company s dedication to attracting and retaining exceptional individuals within the industry. The stock options offer significant potential for financial growth and align the employees interests with the long-term success of the organization.

Companies with similar Income per Employee for 12 month ending Jun 30 2026, within Healthcare Sector

Income per Employee

Income 12 month ending Jun 30 2026

Number of Employees Jun 30 2026

Date modified: 2026-09-08T19:42:27+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.